TY - JOUR
T1 - Cancer vaccines in phase II/III clinical trials
T2 - State of the art and future perspectives
AU - Cecco, S.
AU - Muraro, E.
AU - Giacomin, E.
AU - Martorelli, D.
AU - Lazzarini, R.
AU - Baldo, P.
AU - Dolcetti, R.
PY - 2011
Y1 - 2011
N2 - The topic of this review covers a very important branch of cancer research, cancer vaccination. The growing knowledge in tumor immunology has evolved rapidly, starting from unspecific generic stimulation of the immune system to more specific approaches based on the availability of tumor antigens. The review covers molecular and cell biology, and pharmaceutical technology of cancer vaccines. Particularly, it is aimed at highlighting the results of cancer vaccines from phase II and III clinical trials, an issue that is of relevance to better understand how cancer vaccines can successfully complement antitumor therapy, including conventional chemotherapy and the recently developed target-based drugs.
AB - The topic of this review covers a very important branch of cancer research, cancer vaccination. The growing knowledge in tumor immunology has evolved rapidly, starting from unspecific generic stimulation of the immune system to more specific approaches based on the availability of tumor antigens. The review covers molecular and cell biology, and pharmaceutical technology of cancer vaccines. Particularly, it is aimed at highlighting the results of cancer vaccines from phase II and III clinical trials, an issue that is of relevance to better understand how cancer vaccines can successfully complement antitumor therapy, including conventional chemotherapy and the recently developed target-based drugs.
KW - Cancer
KW - Clinical trials
KW - Immunotherapy
KW - Investigational drugs
KW - Therapeutic vaccines
KW - Tumor-associated antigen
UR - http://www.scopus.com/inward/record.url?scp=78951495136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78951495136&partnerID=8YFLogxK
U2 - 10.2174/156800911793743664
DO - 10.2174/156800911793743664
M3 - Article
C2 - 21062241
AN - SCOPUS:78951495136
VL - 11
SP - 85
EP - 102
JO - Current Cancer Drug Targets
JF - Current Cancer Drug Targets
SN - 1568-0096
IS - 1
ER -